Carcinogenesis Advance Access published online on November 21, 2003
Carcinogenesis, doi:10.1093/carcin/bgh027
© 2003 by Oxford University Press
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
MOLECULAR EPIDEMIOLOGY AND CANCER PREVENTION
1 Section of Cancer Genetics, Institute of Cancer Research, Sutton, Surrey, SM2 5NG, UK; Department of Medicine, Royal Marsden Hospital NHS Trust, SM2 5TT, UK
* Corresponding author. E-mail: richard.houlston{at}icr.ac.uk.
Received 2 July 2003
; revised 15 October 2003
; accepted 11 November 2003
Benign thyroid disorders (BTD) are strong risk factors for non-medullary thyroid cancer (NMTC). Germline variation in Tg (thryoglobulin) and TSHR (thyroid stimulating hormone receptor) confers an increased risk of BTD. To explore the hypothesis that polymorphic variation in these genes affects the risk of NMTC we compared the frequency of TgQ2511R, TSHR-P52T and TSHR-D727E genotypes in two series of NMTC cases and controls (Group 1 - Canadian 102 cases and 102 controls; Group 2 - British 202 cases and 298 controls). No significant association was seen with TSHR-P52T and TSHR-D727E genotypes and risk of NMTC. However, the frequency of the R-allele of TgQ2511R was over represented in NMTC cases in both study populations. The odds ratios associated with hetero- and homozygosity for the R-allele were 1.6 (95% confidence interval, 1.1-2.5) and 2.0 (95% confidence interval, 1.2-3.3) respectively. Although the risk of NMTC associated with the TgQ2511R - R allele is modest, its high prevalence in the general population suggests it may make a significant contribution to the incidence of NMTC.
thyroid carcinoma, polymorphism, thyroglobulin, throtropin receptor
Risk of non-medullary thryoid cancer influenced by polymorphic variation in the thyroglobulin gene
2 Cancer Prevention Center, Sir MB Davis - Jewish General Hospital, McGill University, Montreal, Quebec, H3T 1E2, Canada
3 Section of Cancer Genetics, Institute of Cancer Research, Sutton, Surrey, SM2 5NG, UK
4 Department of Clinical Oncology, Royal Marsden Hospital NHS Trust, SM2 5NG, UK
5 Department of Nuclear Medicine, Guy's & St Thomas' Hospital, London SE1 9RT, UK
6 Cancer Prevention Center, Sir MB Davis - Jewish General Hospital, McGill University, Montreal, Quebec, H3T 1E2, Canada; Division of Medical Genetics, Department of Medicine, Research Institute of the McGill University Montreal General Hospital Research Institute, Montreal, Quebec, H3G 1A2, Canada; Program in Cancer Genetics, Departments of Oncology and Human Genetics, McGill University, Montreal, Quebec, H2W 1S6, Canada
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  A. Baida, M. Akdi, E. Gonzalez-Flores, P. Galofre, R. Marcos, and A. Velazquez Strong Association of Chromosome 1p12 Loci with Thyroid Cancer Susceptibility Cancer Epidemiol. Biomarkers Prev., June 1, 2008; 17(6): 1499 - 1504. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Bethke, A. Murray, E. Webb, M. Schoemaker, K. Muir, P. McKinney, S. Hepworth, P. Dimitropoulou, A. Lophatananon, M. Feychting, et al. Comprehensive Analysis of DNA Repair Gene Variants and Risk of Meningioma J Natl Cancer Inst, February 20, 2008; 100(4): 270 - 276. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Baida, S. M. Farrington, P. Galofre, R. Marcos, and A. Velazquez Thyroid Cancer Susceptibility and THRA1 and BAT-40 Repeats Polymorphisms Cancer Epidemiol. Biomarkers Prev., March 1, 2005; 14(3): 638 - 642. [Abstract] [Full Text] [PDF]
|
|